Clinical observation on biifco combined with triple therapy for eradication of Helicobacter pylori
- VernacularTitle:培菲康联合三联疗法根除幽门杆菌的临床观察
- Author:
Dongzhu PENG
;
Zhongyuan WANG
- Publication Type:Journal Article
- Keywords:
biifco;
triple therapy;
Helicobacter pylori
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):137-138
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efifcacy of biifco combined with triple therapy for eradication of Helicobacter pylori. Methods 84 cases with Helicobacter pylori infection were selected as the observation objects, and were randomly divided into treatment group and control group, 42 cases in each group. Control group used standard triple (omeprazole, amoxicillin, clarithromycin) oral;treatment group took biifco on the basis of control group use. Hp eradication rate, gastrointestinal symptoms and the incidence of adverse reaction in two groups after treatment were compared. Results Hp eradication rate in treatment group was 92.9%, higher than 75.0%in control group, the difference was statistically signiifcant(P<0.05);the incidence of adverse reaction in treatment group was 2.4%, signiifcantly lower than 10.0%in control group, the difference was statistically signiifcant (P<0.05);the total symptom relief rate in treatment group was 90.5%, signiifcantly higher than 75.0%in control group, the difference was statistically signiifcant(P<0.05). Conclusion The eradication rate of biifco combined with triple therapy for Helicobacter pylori is high and signiifcant, which can effectively reduce adverse gastrointestinal reactions.
